Rx direct-to-consumer ads attracting FTC notice, commission attorney tells DIA.
Executive Summary
Rx DIRECT-TO-CONSUMER ADS ATTRACTING FTC NOTICE, Federal Trade Commission Attorney Susan Cohn advised a Drug Information Association meeting on pharmaceutical marketing and promotion March 2 in New York City. "Now that we're seeing an increase in direct-to-consumer advertising, the FTC is watching the direct-to-consumer advertising of prescription drugs," Cohn said. "That's not to say that we've taken any action in the area, or that we're finding a lot to be concerned about, but it is an area that we're watching."
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth